Ampersand Medical's Financing Twist
This article was originally published in Start Up
Executive Summary
If Ampersand Medical Corp. started with an unusual financing strategy, its current efforts to get listed on a major stock exchange are also a bit innovative and circuitous. The fact that it has managed to survive and progress in a tough era for diagnostics, even though it is a late entrant into the crowded field of cervical cancer screening, is a testament to the value of this approach. Its founder, Peter Gombrich, has started several device and diagnostic companies which have acquired each other or licensed from one another, including AccuMed International and InPath. Now, Ampersand wants to buy AccuMed to gain access to short-term revenues, patents, and technologies related to early-stage cancer detection.